Kyorin Pharmaceutical (4569) Earnings: Operating Income Decreased 59.3% YoY to 964 Million Yen, Net Income Down 60.8%

Kyorin Pharmaceutical (4569) has released its financial results, reporting net sales of 29,654 million yen, a 1.9% decrease compared to the same period of the previous year. On the profit front, operating income fell 59.3% year-on-year to 964 million yen, ordinary income decreased 52.7% to 1,241 million yen, and net income attributable to owners of the parent dropped 60.8% to 824 million yen. Comprehensive income also stood at 30 million yen, representing a 98.5% decrease year-on-year.

Despite the decline in earnings for the period, the company maintains a robust financial foundation. The equity ratio stands at a high level of 74.4%, demonstrating strong financial stability. Additionally, retained earnings have accumulated to 130.22 billion yen, providing a solid cushion for the company. Meanwhile, return on equity (ROE) was recorded at 0.64% and return on assets (ROA) at 0.44%, indicating that improving profitability and capital efficiency remain key focal points moving forward. Overall, while current earnings reflect a contraction in profit margins, the company's underlying financial base supported by high equity remains sound.